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ABSTRACT: Human mesenchymal stem cell (hMSC) therapies are
currently progressing through clinical development, driving the need
for consistent, and cost effectivemanufacturing processes tomeet the
lot-sizes required for commercial production. The use of animal-
derived serum is common in hMSC culture but has many drawbacks
such as limited supply, lot-to-lot variability, increased regulatory
burden, possibility of pathogen transmission, and reduced scope for
process optimization. These constraintsmay impact the development
ofaconsistentlarge-scaleprocessandthereforemustbeaddressed.The
aim of this work was therefore to run a pilot study in the systematic
development of serum-free hMSC manufacturing process. Human
bone-marrow derived hMSCs were expanded on fibronectin-coated,
non-porous plasticmicrocarriers in 100mL stirred spinner flasks at a
densityof3 105 cells.mL1 inserum-freemedium.ThehMSCswere
successfully harvested by our recently-developed technique using
animal-free enzymatic cell detachment accompanied by agitation
followedbyfiltrationto separate thehMSCs frommicrocarriers,witha
post-harvestviabilityof99.63 0.03%.ThehMSCswerefoundtobein
accordance with the ISCT characterization criteria and maintained
hMSCoutgrowth andcolony-forming potential. ThehMSCswere held
in suspension post-harvest to simulate a typical pooling time for a
scaled expansion process and cryopreserved in a serum-free vehicle
solution using a controlled-rate freezing process. Post-thaw viability
was75.8 1.4%withasimilar3 hattachmentefficiencyalsoobserved,
indicating successful hMSC recovery, and attachment. This approach
therefore demonstrates that once an hMSC line and appropriate
medium have been selected for production, multiple unit operations
can be integrated to generate an animal component-free hMSC
production process from expansion through to cryopreservation.
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Introduction
Regenerative medicine (RM) is a growing field that aims to treat
currently unmet clinical indications such as diabetes, cardiovas-
cular disease, and neurological disorders by restoring or
maintaining tissue function. Cell-based therapies form an integral
part of the RM industry with the potential, if properly developed, to
transform global healthcare. Ever since the termmesenchymal stem
cell was first introduced (Caplan, 1991), much anticipation has been
generated around the potential for hMSCs to treat and in some cases
cure human disease. This anticipation has been largely driven by
their relative ease of isolation, their ability to proliferate ex vivo
under appropriate culture conditions and their capacity to secrete a
range of trophic factors which regulate host immune response and
initiate tissue repair (Caplan and Dennis, 2006). Consequently,
hMSCs are advancing through clinical development targeting
clinical indications such as acute coronary syndrome, stoke, and
graft vs. host disease (Heathman et al., 2014).
Despite this progress, many challenges remain before cost
effective production, storage, and delivery of hMSCs to the clinic
is feasible. For clinical indications where the direct transplant of
primary donor hMSCs is insufficient, the expansion of cells in
vitro is necessary to increase cell numbers without negatively
impacting the therapeutic potency of the cell. The expansion of
hMSCs has traditionally taken place in planar tissue culture
flasks; however considering that the required manufacturing lot
sizes for allogeneic hMSC therapies are likely to be in the order of
trillions of cells (Rowley et al., 2012), these systems may not be
adequate to fulfill this need. For processes to drive towards the
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production of cost effective therapies, they should be scalable,
compliant with Good Manufacturing Practices (GMP), and be
amenable to closed and automated process steps. The addition of
microcarriers has been used to culture adherent cells such as
hMSCs in suspension (Rafiq et al., 2013) allowing for process
scale up, where online monitoring, and control systems can be
used to deliver a consistent and cost-effective hMSC product.
Stirred-suspension bioreactors are currently employed for
mammalian cell culture in biopharmaceutical production and
therefore their design and operation are well-understood
(Nienow, 2006), with the potential to meet the expected
manufacturing demands of large-scale hMSC therapies.
A key aspect of reducing variation in the process will be
reducing and eventually eliminating the use of fetal bovine
serum (FBS) from the cell culture medium (Wappler et al.,
2013). In addition to lot-to-lot variability, there are further
process constraints on the use of FBS such as limited supply
(Brindley et al., 2012), spiraling cost, potential for pathogen
transmission, increased risk of recipient immune reaction
(Spees et al., 2004), and reduced scope for process optimization.
Furthermore, FBS has been shown to contain immunogenic
contaminants which have the potential to negatively impact
post-transplant clinical results (Heiskanen et al., 2007),
potentially increasing the regulatory burden placed upon these
products. All of these considerations mean that moving towards
a serum-free process would be beneficial in achieving scalable,
tunable, and consistent hMSC manufacturing processes. In
addition, hMSCs grown in a serum-free medium have
demonstrated increased proliferation rates, up-regulation of
genes important in hMSC function, and down-regulation of
genes involved in the production of proinflammatory cytokines
(Crapnell et al., 2013).
Unlike traditional suspension-based bioprocesses, cell har-
vesting from the microcarrier surface is critically important as
the quality characteristics of hMSCs must be retained
throughout this process. Harvesting involves two stages,
detachment of hMSCs from microcarriers followed by micro-
carrier separation from the hMSC product (Nienow et al., 2014).
After separation, cell-based products will undergo a holding
time prior to downstream processing and formulation in order
to pool the product. Product quality can deteriorate with
prolonged holding time (Pal et al., 2008) and should be
considered during process development. The large scale
manufacture of an allogeneic hMSC product will require long
term product storage to decouple production from delivery, in a
business model akin to current biopharmaceuticals. Therefore,
cryopreservation of hMSCs must be carefully considered to
ensure the therapeutic potential of the hMSC product does not
deteriorate prior to delivery (Moll et al., 2014).
This study demonstrates for the first time that human hMSCs
can be expanded, harvested, separated, cryopreserved, and
recovered from a potentially scalable serum-free microcarrier
process. The successful integration of sequential unit operations for
a serum-free hMSC production process from expansion through to
cryopreservation provides an important pilot study in the
development of a scalable manufacturing process for hMSC
therapies.
Materials & Methods
Monolayer Culture
Human MSCs were isolated from bone-marrow aspirate purchased
from Lonza (Walkersville, MD, USA) obtained from a healthy donor
with informed consent. The localEthical Committee approved theuse
of the sample for research. Cells frompassage 1were cryopreserved at
a density of 1–2 106 cells.ml1 in in a freeze medium containing
90% (v/v) FBS (Hyclone, Belgium) and 10% (v/v) dimethylsulph-
oxide (Sigma–Aldrich, Gillingham,UK). Cells were grown in T-flasks
seeded at 5,000 cells.cm2 at 37C in humidified air containing 5%
CO2. For serum-based culture, Dulbecco’s Modified Eagles Medium
(DMEM, 1 g/L glucose; Lonza, UK) supplemented with 10% (v/v)
FBS (Hyclone, Belgium), and 2mM UltraGlutamine (Lonza, Slough,
UK) was exchanged every 3 days. For serum-free culture, the growth
surface of T-flaskswas coatedwith 0.4mg.cm2 PRIME-XV
TM
human
fibronectin (FN, Irvine Scientific, Santa Ana, CA) and cultured in
PRIME-XV
TM
SFM (Irvine Scientific) as per manufacturer’s
instructions. On passage, the hMSCs were washed with phosphate
buffered saline (PBS) and incubated for 4 min with trypsin
(0.25%)/EDTA (Lonza, UK) or TrypLE Express (Invitrogen, UK).
Dissociation reagentswere inactivated by the addition of appropriate
growth medium and the cell suspension was centrifuged at 220 g for
5min. The supernatant was discarded and the remaining pellet was
re-suspended in an appropriate volume of culture medium. For
serum-free experiments, hMSCs underwent one adaptation passage
in serum-free medium.
Spinner Flask Culture
The glass surfaces of 100mL Spinner flasks (diam. T¼ 60mm,
BellCo, USA) with a magnetic, horizontal stirrer bar, and a vertical
paddle (diam. D¼ 50mm) were siliconized with Sigmacoat
(Sigma–Aldrich) according to manufacturer instructions. Solid,
non-porous Plastic P-102L microcarriers of 160-200 microns
(Solohill, USA) were prepared at 500 cm2 per 100mL following
manufacturer’s instructions. Microcarriers were preconditioned in
50mL FBS-containing growth medium for 1 h or coated with
0.1mg.cm2 FN prior to hMSC inoculation at 6,000 cells.cm2 and
cultured in 100mL of FBS-containing or PRIME-XV
TM
SFM at 37C
in humidified air containing 5% CO2. A 50% medium exchange was
performed every three days for FBS-containing medium and every
2 days for PRIME-XV SFM as per manufacturer’s instructions.
Following inoculation the culture was static for 1 h, after which the
culture was agitated constantly at the minimum rate for suspension
(NJS) found to be 30 rpm, with daily medium samples of 1 mL taken
for analysis.
Analytical Techniques
Analysis of glucose, lactate, ammonia, lactate dehydrogenase
(LDH), and total protein was performed using a Cedex Bio-HT
(Roche, Germany). Cell counting, mean cell diameter, and viability
(via acridine orange uptake and DAPI exclusion) was performed
using a NucleoCounter NC-3000 automated mammalian cell
counter (Chemometec, Denmark). Microcarrier-based cell counts
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were obtained whilst the cells were still attached to microcarriers.
The following parameters were obtained:
Specific Growth Rate
Specif ic growth rate;m ¼ InðcxðtÞ=cxð0ÞÞ
Dt
where m is the net specific growth rate (h1), Cx(t), and Cx(0) are
the cell numbers at the end and start of the exponential growth
phase, respectively and t is time (h).
Population Doublings
Population Doublings; Pd ¼ 1logð2Þ  log
cxðtÞ
cxð0Þ
 
where Pd is the number of population doublings, Cx(t), and Cx(0)
are the cell numbers at the end and start of the exponential growth
phase, respectively.
Specific Metabolite Consumption/Production Rate
Specif ic metabolite f lux; qmet ¼
m
cxð0Þ
 
 cmetðtÞ  cmetð0Þ
emt  1
 
where qmet is the net specific metabolite consumption or production
rate, m is the specific growth rate (h1), Cx(0) is the cell number at
the end of the exponential growth phase, Cmet(t), and Cmet(0) are
the metabolite concentrations at the end and start of the
exponential growth phase, respectively and t is time (h).
Microcarrier Harvest
The hMSCs were harvested using a recently developed method
(Nienow et al., 2014). Briefly, culture mediumwas removed from the
spinner flask and the cells on the microcarriers were washed twice
with 100mL Ca2þ and Mg2þ free phosphate buffered saline (PBS).
The cells were then detached by the use of 50mL of dissociation
enzyme (either TrypLE Express [Invitrogen, UK] or Trypsin [0.25%,
w/v]/ EDTA [Lonza, UK]) whilst agitating at 150 rpm for 7–10min
and 250 rpm for the final few seconds. Following detachment, hMSCs
were separated from the microcarriers by vacuum filtration using a
60mmSteriflip
1
filter (Millipore, USA). The cell suspensionwas then
centrifuged and re-suspended in the appropriate culture medium.
hMSC Characterisation
Immunophenotype analysis was performed post microcarrier
harvest using an established multiparameter-based protocol (Chan
et al., 2014). Cell viability on microcarriers was assessed by a Nikon
Eclipse TS100 fluorescence microscope (Nikon Instruments Europe
B.V. UK) using the LIVE/DEAD
1
(Calcein-AM/Ethidium Homo-
dimer) Viability/Cytotoxicity Kit (Invitrogen, USA) as per manu-
facturer’s instructions. Colony forming unit-fibroblast (CFU-F)
efficiency was determined by culturing T-flasks seeded at 100 cells.
cm2 for 14 days, fixing colonies with 4% (v/v) formaldehyde
(Sigma–Aldrich), and staining with 1% (w/v) crystal violet solution
(Sigma–Aldrich). Colonies with at least 25 cells were counted and
CFU-F potential calculated based on the seeded cell number.
The hMSC differentiation was induced using PRIME-XV
TM
hMSC
Differentiation Medium (Irvine Scientific, USA) as per manufac-
turer’s instructions. After 21 days the differentiation media were
removed, cells rinsed with PBS then fixed with 4% (v/v) PFA at
Figure 1. Process map for the serum-free expansion, harvest, downstream processing and preservation of hMSCs on microcarriers.
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room temperature. Adipocytes were stained with 1% (w/v) Oil Red
O (Sigma–Aldrich) in isopropanol at room temperature and rinsed
with distilled water. Osteoblasts were incubated with 2.5% (v/v)
silver nitrate (Sigma–Aldrich) under ultraviolet light (30min
exposure), rinsed with distilled water, and stained with fast violet
solution (Sigma–Aldrich) containing 4% (v/v) napthol AS-MX
phosphate alkaline (Sigma–Aldrich) for 45min at room temper-
ature in the dark. Chondrocytes were stained with 1% (w/v) Alcian
blue (Sigma–Aldrich) in 0.1 M hydrochloric acid (Sigma–Aldrich).
After 30min incubation, cells were rinsed three times with 0.1M
HCl. After staining, differentiated cells were visualized under a light
microscope (Nikon Eclipse TS-100, UK).
Cryopreservation and Thaw
Following detachment and separation from the microcarriers, hMSCs
were held in culture medium for 4 h to simulate an expected process
pooling time. Harvested cells were then suspended in Prime-XV
TM
Cryopreservation medium (Irvine Scientific, USA) at 2 106 viable
cells.ml1. Cells were equilibrated in freezing medium for 30min at
room temperature and aliquots (0.5ml) were loaded into 1.8ml
cryovials during equilibration. Vials were cooled at 4C for 5min then
cooled with a Stirling cryocooler (EF600, Asymptote, UK) set to cool at
1C.min1 to80C. Cooled vials were stored under liquid nitrogen
vapor for at least one month. Vials were rapidly thawed in a 37C water
bath and cells recovered by growth medium dilution followed by
centrifugation. The resultant cell pellet was suspended in growth
medium then the cells were seeded into T-flasks to monitor outgrowth
and into fibronectin-coated multiwell plates to assess cell adhesion.
For the cell adhesion assay, cultured cells were washed with PBS
then fixed and permeabilized with BD Cytofix/Cytoperm
TM
kit at 4C
for up to 1 week. After repeated washing, cellular F-actin was stained
with 100 nM Alexa Fluor
1
Phalloidin with 100 nM 40,6-diamidino-2-
phenylindole counterstain for 30min in the dark. Stained cells were
visualized with a Nikon Eclipse TS100 fluorescence microscope
(Nikon Instruments Europe B.V. UK). Cells were harvested during
outgrowth and diluted 1:1 with viability stain (10 nM calcein-
AMþ 50mg/ml propidium iodide in PBS) and incubated at 37C for
7min in 96 well plates. Stained cells were counted using a Guava
EasyCyte 8HT flow cytometer using a standardized analysis protocol
with GuavaSoft 2.6 (Merck Millipore, UK).
Statistical Analysis
Results were deemed to be significant if P< 0.05 using a two-tailed
Students t-test.
Results & Discussion
Process Map of hMSC Production Process
Process mapping is a key part of systematic process development
and allows for a structured development methodology centered on
the concept of integrated unit operations and is being adopted in
Figure 2. Growth kinetics of hMSCs cultured on microcarriers in FBS-containing medium and serum-free medium. Showing (A) Total viable cell number, (B) Specific growth
rate, (C) Cell concentration and (D) cumulative population doublings. Data shows meanSD n¼ 3.
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current biopharmaceutical manufacture (ICH, 2005). Breaking a
process down into unit operations allows for the detailed analysis of
each process sub-unit, which can be assessed in terms of its impact
on the product characteristics. This flags potential issues or
bottlenecks in the process which can then be systematically
resolved. Figure 1 shows our simplified process map, which forms
the basis for our integrated serum-free hMSC production process,
allowing us to develop individual unit operations to eventually
achieve a larger yield of high quality product. The timing of the
microcarrier-fibronectin coating step has been highlighted as a
potential bottleneck, which cannot take place immediately prior to
the expansion step. A quality risk management approach has
highlighted that the quality assurance of the microcarrier coating
could not take place in-process, as a failure event would severely
impact subsequent unit operations. This will be addressed during
future process development as this unit operation would have to
take place in advance to decouple the coating step from the hMSC
expansion, reducing the inherent risk in the process.
A further benefit of the process map is that it allows for
interchangeability of unit operations that may not be sufficiently
scalable for future product requirements. An example of this in our
current process is the use of vacuum filtration and centrifugation to
separate the hMSCs from the microcarriers, which would be a
challenge to operate at large scale. Therefore, during future
development, scalable technology would be assessed for the
separation, and concentration step such as tangential-flow
filtration. The effect of this unit operation must be assessed in
terms of the impact on the product characteristics, to ensure
product quality is not compromised. This assessment should
be done in a timely manner, as the implications of changing
process unit operations late in clinical development can be
prohibitive. Therefore by taking this systematic development
methodology and utilizing process mapping, potential bottlenecks,
and scalability issues can be alleviated at an early stage of
development, avoiding costly changes as processes move through
clinical development.
Expansion
As described previously, intensive process scale-up will be required
to meet the clinical and commercial need for these large-scale
allogeneic therapies. For instance, for a typical clinical indication
like myocardial infarction, the dose requirements will be in the
range of 35–350 million hMSCs per patient (Hare et al., 2009).
The hMSCs were expanded on non-porous plastic microcarriers
in 100mL spinner flasks over six days in FBS-containing medium
and PRIME-XV SFM
TM
. To facilitate cell attachment without the
presence of serum (Hayman et al., 1985), plastic microcarriers
were pre-coated with fibronectin before expansion under serum-
free conditions. For hMSCs expanded in spinner culture with
Figure 3. Microcarrier culture of hMSCs on day 5 showing representative images of cell-microcarrier aggregation. Image of microcarriers in spinner flask with FBS-containing
medium (A) and serum-free medium (B). Live/dead cell stain of hMSCs onmicrocarriers in FBS-containingmedium (C) and serum-free medium (D). Live cells stained with Calcein AM
fluorophore (GREEN) and dead cells are stained with ethidium homodimer (RED).
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FBS-containing medium, a final cell density of (8.58 1.37) x
104 cells.mL1 (mean SD, n¼ 3) was reached, corresponding to
a fold expansion of 2.86 0.46 (Fig. 2). In contrast, hMSCs
expanded in serum-free medium reached a final cell density of
(3.01 0.27) x 105 cells.mL1, corresponding to a fold increase of
10.04 0.88 over the same time period (Fig. 2). Operating under
serum-free conditions gave a 350% increase in hMSC yield, which is
significantly higher than serum-based culture (P< 1  106). This
difference represents a significant step forward in increasing the lot-
size of hMSC expansion and is comparable to studies which have
achieved a cell density of hMSCs cultured on microcarriers of 1–
2 105 cells.mL1, also under serum-free conditions (dos Santos
et al., 2014; Santos et al., 2011). It was also observed that the
hMSC growth kinetics under serum-free microcarrier culture
(0.384 0.014 day1) were significantly higher (P< 0.0001) than
serum-free monolayer culture (0.323 0.011 day1). This increase
could also be improved further by adding more surface area during
the microcarrier culture, reducing the surface area limitation
experienced under serum-free conditions.
Despite this improvement in hMSC yield under serum-free
conditions, the expansion unit operation is clearly far from optimal.
Figure 3 shows the large amount of microcarrier aggregation that
occurred in serum-free culture, which limited the effective surface
area available for expansion. The growth kinetics in figure 2B and D,
where the hMSC growth between day 3–6 was reduced compared to
day 0–3 in serum-free culture, is also suggestive of surface area
limitation. It is likely that microcarrier aggregation is caused by a
combination of accelerated cell growth, the microcarriers reaching
effective confluence, and the medium sampling process which
requires the microcarriers to settle. These potential mechanisms will
need to be addressed moving forward as aggregation not only has the
potential to reduce cell yield but can also accentuate cell micro-
environment heterogeneity (Baraniak et al., 2012) resulting in a cell
product of inconsistent quality, although this did not happen here.
Metabolite analysis of microcarrier-based suspension culture of
hMSCs showed differences in the metabolic pathway usage relating
to lactate and ammonia production between FBS-containing and
serum-free cultures. In FBS-containing medium, hMSCs favored the
relative production of lactate over ammonia, whereas the relative
production of ammonia over lactate was favored with hMSCs
cultured in serum-free conditions (Fig. 4). Figure 5 shows that the
per cell production of lactate was lower in serum-free culture at
12.63 0.59 pmol.cell1.day1 (mean SD, n¼ 3) compared
with 20.81 4.88 pmol.cell1.day1, whereas the production of
ammonia was 2.82 0.15 pmol.cell1.day1 in serum-free, com-
pared to 3.31 0.10 pmol.cell1.day1 in FBS-containing culture.
The estimated yield of lactate from glucose over the entire culture
period was 1.91 0.03 and 1.76 0.04 mollactate.molglucose1 for
FBS-containing and serum-free culture, respectively. We consider
the observed differences in these metabolic profiles to be
predominantly related to proliferative rate in this instance. The
increased proliferative rate coupled with the smaller cell size makes
Figure 4. Nutrient and metabolite flux of hMSC expansion on microcarriers. Glucose, lactate and ammonia concentrations in FBS-containing medium (A) and serum-free
medium (B). Total protein (C) and lactate dehydrogenase concentration (D) are shown for FBS-containing and serum-free medium. Data shows mean SD, n¼ 3.
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DNA a larger proportion of the total cell biomass under serum-free
conditions (Fig. 7C). Increased ammonia production suggests
altered amino acid utilization, which may be related to the increased
need for precursors (e.g., glutamine and asparagine) supporting
purine, and pyrimidine biosynthesis (Higuera et al., 2012). It is
clear that a more detailed metabolic analysis is required and the
development of culture medium should consider the impact of these
metabolic pathways on cell characteristics. The reduced con-
sumption of glucose and production of lactate per cell under serum-
free conditions does however provide an advantage over serum-
based culture, as the usage, and build-up of metabolites has the
potential to inhibit cell growth as the yield and scale increases.
Growth limiting concentrations of lactate and ammonia for
hMSCs, reported as 35.4 mM and 2.4 mM, respectively (Schop et al.,
2009), were not reached in any of our microcarrier cultures. Cell
death was evaluated by measuring a combination of lactate
dehydrogenase (LDH, Lavrentieva et al., 2010) and total protein
released. Figure 4C and 4D show these concentrations throughout
culture, which indicate only a minimal increase in LDH, and no
change in the total protein released. This demonstrates that cell
death was minimal throughout the expansion process, despite the
increase in microcarrier aggregation, making the fold expansion
data a reliable estimate of net proliferative rate.
Harvest
The post-expansion detachment and separation of the hMSC
product from the microcarrier surface, whilst retaining the cell
quality, is of critical importance for a scalable production process.
The sequential expansion and harvest of hMSCs represents an
important step in the successful integration of these unit operations
and has been demonstrated previously by our group in a FBS-based
culture (Nienow et al., 2014). The same harvest protocol was
modified for this study by replacing trypsin-EDTA with TrypLE
Express for the serum-free culture to ensure the process was
animal-component free. It was also observed that though
microcarrier aggregation and cell number in the serum-free
process was significantly greater than FBS-based culture, this
difference did not limit the effectiveness of the harvest protocol, and
the hMSCs were successfully detached from themicrocarrier surface
(Fig. 6), with post-harvest cell viability (based on membrane
integrity) of 99.63 0.03% (mean SD, n¼ 3).
After separating the cells from the microcarriers by vacuum
filtration, the hMSCswere held in culturemedium at room temperature
to simulate a potential large-scale batch pooling time before
centrifugation, freezing medium equilibration, and cryopreservation.
This holding stepwas considered important for a cell-based product, as
a hMSC holding time of greater than 6 h has been shown to negatively
impact cellular quality (Pal et al., 2008), which could impose limits on
the potential scalability of the bioprocess, depending on the sensitivity
of the cell-basedproduct. This holding process canbe brokendown into
the microcarrier harvest (2 h process) and microcarrier-cell separation
with an ambient hold in culture medium (2 h process). These steps are
followed by suspension and equilibration of the cell product in freeze
medium for up to 1 h at 4C prior to cryopreservation, which should be
an acceptable exposure time for mixing and dosing thousands of vials
or bags with suitable manifold filling systems (Rowley et al., 2012).
Tangential-flow filtration has the potential to wash and concentrate cell
products at the large scale within this 2 window (Pattasseril et al.,
2013), meaning that the combined harvest, downstream, and
Figure 5. Specific consumption rate per cell of glucose (A) and production rate per cell of lactate (B), ammonia (C) and lactate dehydrogenase (D) for FBS-containing medium
and serum-free medium. Data shows mean SD (n¼ 3).
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preservation timings in this study would still be relevant as the process
is scaled-up further (Heathman et al., 2014).
Post-Harvest Characterisation
To ensure that the microcarrier-based expansion and harvest unit
operations have not had a detrimental effect on identity and quality,
hMSC characteristics have been evaluated immediately post-harvest.
The primary objective for this is to demonstrate that the hMSCs
conform to the International Society for Cellular Therapy (ISCT)
criteria (Dominici et al., 2006). Figure 8 shows the compliance of the
hMSCs with the ISCT criteria, by adherence to tissue culture plastic,
demonstrating the same morphology post-harvest as was demon-
strated pre-expansion, and differentiation down the osteogenic
(Fig. 8E), adipogenic (Fig. 8F), and chondrogenic (Fig. 8G) lineages.
The post-harvest hMSC immunophenotype can be seen in Figure 8H
which shows the co-expression of positivemarkers CD73, 90, and 105
at greater than 99% as well as the expression of HLA-DR at less than
2% (Chan et al., 2014). There was an increase in the positive
expression of CD34 above the 2% positive threshold, which can be
attributed to an increase in non-specific antibody binding caused by
the culture of hMSCs on a fibronectin substrate (data not shown), and
has previously been reported to be positive for adipose derived
hMSCs (Wagner et al., 2005).
Figure 7. Post-harvest hMSC quality compared to pre-expansion demonstrating retention of key attributes, showing (A) specific growth rate, (B) colony forming efficiency, (C)
mean cell diameter and (D) forward/side scatter of cell populations confirming difference in mean cell diameter.
Figure 6. Post-expansion harvest of hMSCs from microcarriers showing
successful hMSC detachment from microcarriers (A). Post-harvest viability shows
high number of intact hMSCs for FBS-containing medium and serum-free medium.
Data shows mean SD, n¼ 3.
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Figure 8. Post-harvest hMSC characterisation. (A) pre-expansion and (B) post-harvest hMSC morphology in FBS-containing medium. (C) pre-expansion and (D) post-harvest
hMSC morphology in serum-free medium. Tri-lineage differentiation of hMSCs showing (E) osteogenic, (F) adipogenic and (G) chondrogenic potential post-harvest in serum-free
medium. Multiparameter flow cytometry showing dual gating of CD73, 90, 105, 34 and HLA-DR for hMSCs post-harvest from serum-free microcarrier culture (H).
Figure 9. Post-thaw hMSC recovery following serum-free cryopreservation, showing (A) post-thaw recovery and 3 h cell attachment based on PI exclusion. Post-thaw hMSC
outgrowth (B) following serum-free cryopreservation. Data shows mean SD (n¼ 3).
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The successful development of a hMSC manufacturing process
relies on the characterization of product identity and quality at each
unit operation (Carmen et al., 2012). The development of clinical
indication specific hMSC quality assays has proved to be complex,
owing to their unique and multifactorial putative mechanism of
action.Without definitive quality assays, we rely on surrogate assays
to measure cell attributes that are known to be related to aspects of
hMSC quality. Figure 8A shows the outgrowth of hMSCs before,
during and after expansion, with no decline in the proliferative
potential observed across these unit operations. This suggests that
hMSCs have not experienced detrimental conditions during the
microcarrier expansion and harvest process that could have affected
their proliferation potential (Sethe et al., 2006).
Colony forming potential has been highlighted as an important
assay for the quality of hMSC preparations (Pochampally 2008) and
is known to deteriorate during culture (Schellenberg et al., 2012).
Figure 8B shows the maintenance of colony forming potential from
pre-expansion to post harvest for both conditions, which further
demonstrates that the hMSCs have not been damaged during the
harvest, and separation process.
The size of hMSCs in culture is known to increase as they
undergo cellular senescence (Wuchter et al., 2015), and should
therefore be tracked throughout expansion and harvest to ensure it
remains stable. Figure 8C demonstrates that the mean cell diameter
remained stable throughout culture, with significantly smaller
hMSCs produced under serum-free culture (P< 0.05). Without the
availability of a robust potency assay to determine the implications
of a smaller cell size in serum-free culture, it is not known how this
will affect in vivo hMSC quality attributes. Despite this, clinical
work has demonstrated that smaller hMSCs reduce the potential for
vascular obstructions and stroke following the intra-artery
injection of cells (Ge et al., 2014), as well as reducing capillary
entrapment (Dreher et al., 2013). These observations suggest that a
smaller cell size may not only be beneficial in terms of obtaining a
higher number of cells per area for expansion, but might also be
advantageous in product delivery. This possibility raises a question
of whether the therapeutic potential of the cell is related to size and
whether we need to think not only in terms of cell number but also
in terms of product biomass for production and delivery of cell
therapies. Cellular enlargement has been associated with the
development of professional secretory cells such as plasma cells
(Shaffer et al., 2004), with more organelles and increased protein
synthesis. Considering that protein secretion is a putative
mechanism of action of hMSCs in vivo, the relation of cell size
to secretory capability of hMSCs should be clinically evaluated post-
delivery.
Cryopreservation and Recovery
The hMSCs harvested from serum-free spinner cultures were
preserved using a serum-free freezing medium and a slow-freezing
cryopreservation process. After thawing, cell viability (by
membrane integrity) decreased to 75.8 1.4% as a consequence
of the cryopreservation process (Fig. 9A). However, this value
remains above the FDA guideline for cell-based therapies of 70%
(FDA, 2008). A similar number of cells were recovered after 3 h in
culture, based on their sustained adherence to fibronectin without
loss of membrane integrity (Fig. 9A). It is important to note that this
post-thaw recovery is comparable to studies where hMSCs have
been immediately processed from monolayer culture (Liu et al.,
Figure 10. Post-thaw hMSC recovery following serum-free cryopreservation, demonstrating formation of F-Actin cytoskeleton (A) 3 h, (B) 24 hours post thaw (C) 3 h post-
passage control and (D) 24 hours post-passage control. Phase contrast images show day 2 hMSC morphology post-thaw (E) and post passage control (F). Scale bar¼ 250mm.
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2010), without the microcarrier harvest, filtration, and holding
time steps.
Despite the initial cell loss post-thaw, a 500% increase in cell
yield was obtained after 7 days in monolayer culture (compared
with 800% for unpreserved post-passage control), showing that
recovered cells were able to proliferate normally (Fig. 9B).
Recovered cells also displayed comparable morphology to
unpreserved cells after 3 h and 24 h of culture on fibronectin,
with signs of matured cell-matrix interactions, cell elongation
(indicative of motility, Huttenlocher and Horwitz, 2011), and
recovery of F-actin networks (Fig. 10). These observations
demonstrate that hMSCs can be cryopreserved and recovered
from a microcarrier expansion, harvest, and holding process, with
comparable cell yields to traditional monolayer harvest and
immediate cell preservation.
Conclusions
This study has demonstrated the feasibility of a serum-free
microcarrier process for the expansion, harvest and preservation of
hMSCs. The integration of multiple process unit operations is an
important step in developing a microcarrier-based expansion
process capable of meeting the lot sizes required for clinical
applications. The hMSC identity and quality have been maintained
throughout every unit operation of this integrated process,
culminating with the successful recovery of hMSCs from the
cryopreservation step. Mapping has provided a robust process
understanding from end-to-end, which can be broken down into
individual unit operations and optimized for hMSC yield, quality,
and consistency. The systematic development of a process control
system for the expansion step will form a key part of this, as well as
the identification and mitigation of bottlenecks to further
streamline the process.
This study has been funded by the Engineering and Physical Sciences
Research Council (EPSRC), the Biotechnology and Biological Sciences
Research Council (BBSRC) and FUJIFILM Diosynth Biotechnologies.
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